Paragon 28, Inc. (NYSE: FNA) has released its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024. The company's preliminary unaudited net revenue for the fourth quarter of 2024 is expected to be in the range of $71.5 to $71.8 million, which represents reported growth of approximately 18.0% to 18.5% compared to the fourth quarter of 2023.
For the full year of 2024, the preliminary unaudited net revenue is expected to be in the range of $255.9 to $256.2 million, indicating reported growth of approximately 18.2% to 18.4% compared to the full year of 2023.
These figures reflect a transformative year for Paragon 28, characterized by significant achievements in growth, innovation, and operational efficiency. The company's efforts have delivered tangible results, positioning them for sustainable, profitable growth in the future.
Albert DaCosta, Chairman and CEO of Paragon 28, expressed excitement about building on this momentum and redefining what is possible in the foot and ankle market in 2025. As a leading medical device company exclusively focused on the foot and ankle orthopedic market, Paragon 28 is dedicated to improving patient lives through innovative orthopedic solutions, procedural approaches, and instrumentation.
It's important to note that the estimated unaudited financial results are subject to the close of the quarter and year, completion of quarter-end and year-end closing procedures, and further financial review. The actual results may differ from these estimates due to the completion of closing procedures, review adjustments, and other developments that may arise before the financial results for the fourth quarter and year are finalized. Following these announcements, the company's shares moved 3.4%, and are now trading at a price of $10.7. Check out the company's full 8-K submission here.
